CORE-URO-01 study: comparison of safety and efficacy of pazopanib in first-line metastatic renal cell carcinoma (mRCC) with or without renal failure

被引：0
|
作者：
Masini, C. [1 ]
Vitale, M. G. [1 ]
Maruzzo, M. [2 ]
Procopio, G. [3 ]
De Giorgi, U. [4 ]
Buti, S.
Rossetti, S. [5 ]
Iacovelli, R. [6 ]
Guida, A. [7 ]
Atzori, F. [8 ]
Mucciarini, C. [9 ]
Scagliarini, S. [10 ]
Vignani, F. [11 ]
Prati, G. [12 ]
Cosmai, L. [13 ]
Berselli, A. [1 ]
Pinto, C. [1 ]
机构：
[1] Azienda Osped Arcispedale Santa Maria Nuova, IRCCS, Oncol Unit, Reggio Emilia, Italy
[2] Ist Oncol Veneto IRCCS, Oncol Unit, Padua, Italy
[3] FONDAZIONE IRCCS INT Milano, Oncol Unit, Milan, Italy
[4] Ist Tumori Romagna IRST, Oncol Unit, Meldola, Italy
[5] Fdn Pascale, IRCCS, Ist Nazl Tumori, Div Med Oncol,Dept Urogynaecol Oncol, Naples, Italy
[6] Univ Integrata Verona, Azienda Osped, Oncol Unit, Verona, Italy
[7] Univ Policlin Modena, Azienda Osped, Oncol Unit, Modena, Italy
[8] Azienda Osped Univ Cagliari, Oncol Unit, Cagliari, Italy
[9] Ramazzini Hosp, Med Oncol, Carpi, Italy
[10] Azienda Osped Antonio Cardarelli, Oncol Unit, Naples, Italy
[11] AO Ordine Mauriziano, Oncol Unit, Turin, Italy
[12] AO Ordine Mauriziano, Med Oncol, Guastalla, Italy
[13] Ist Ospitalieri Cremona, Nephrol Unit, Cremona, Italy
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
905P
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Efficacy and Safety of Pazopanib in Patients With Metastatic Renal Cell Carcinoma
    Hutson, Thomas E.
    Davis, Ian D.
    Machiels, Jean-Pascal H.
    De Souza, Paul L.
    Rottey, Sylvie
    Hong, Bao-fa
    Epstein, Richard J.
    Baker, Katherine L.
    McCann, Lauren
    Crofts, Theresa
    Pandite, Lini
    Figlin, Robert A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (03) : 475 - 480
  • [22] TOLERABILITY OF TARGETED AGENTS IN FIRST-LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA (MRCC)
    Su, Y.
    Shi, N.
    Landsman-Blumberg, P.
    Poehlein, C.
    Waxman, I.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 267 - 268
  • [23] Real world outcomes of patients with metastatic renal cell carcinoma (mRCC) using first-line sunitinib or pazopanib: the Canadian experience
    Lalani, A-K.
    Li, H.
    Heng, D.
    Wood, L.
    Kalirai, A.
    Bjarnason, G.
    Sim, H-W.
    Kollmannsberger, C. K.
    Kapoor, A.
    Hotte, S. J.
    Vanhuyse, M.
    Czaykowski, P.
    Reaume, M. N.
    Soulieres, D.
    Venner, P.
    North, S.
    Basappa, N.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [24] Comparative effectiveness of combination first-line therapies for metastatic renal cell carcinoma (mRCC).
    Shay, Rebecca C.
    Nicklawsky, Andrew
    Lam, Elaine Tat
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [25] Efficacy and safety of pazopanib as a subsequent treatment after failure of other targeted agents in patients with metastatic renal cell carcinoma (mRCC).
    Tan, Jiahuai
    Heilbrun, Lance K.
    Fontana, Joseph A.
    Smith, Daryn
    Heath, Elisabeth I.
    Baranowski, Karen
    Vaishampayan, Ulka N.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [26] Safety and efficacy of tivozanib in first-line metastatic renal cell carcinoma: A multicenter compassionate use study
    Basso, Umberto
    Procopio, Giuseppe
    Fornarini, Giuseppe
    Massari, Francesco
    Bearz, Alessandra
    Fratino, Lucia
    Milella, Michele
    Bassanelli, Maria
    Sacco, Cosimo
    Bimbatti, Davide
    Verzoni, Elena
    Rizzo, Mimma
    Porta, Camillo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [27] Broad immunomodulating effect of first-line Pazopanib in metastatic renal cell carcinoma patients
    Verzoni, E.
    Cova, A.
    Squarcina, P.
    De Cecco, L.
    Rinchai, D.
    Bedognetti, D.
    Grassi, P.
    Ratta, R.
    Procopio, G.
    Rivoltini, L.
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [28] Economic evaluation of pazopanib as first-line treatment of metastatic renal cell carcinoma in Greece
    Solakidi, A.
    Kourlaba, G.
    Kontovinis, L.
    Bournakis, E.
    Boutis, A.
    Koutsoukos, K.
    Syrios, J.
    Tzovaras, A.
    Chatzikou, M.
    Michailidi, C.
    Maniadakis, N.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [29] Broad immunomodulating effect of first-line pazopanib in metastatic renal cell carcinoma patients
    Verzoni, E.
    De Cecco, L.
    Dugo, M.
    Rinchai, D.
    Bedognetti, D.
    Grassi, P.
    Ratta, R.
    Cova, A.
    Squarcina, P.
    Huber, V.
    Montone, R.
    Sorrentino, M.
    Procopio, G.
    Rivoltini, L.
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [30] Combination nivolumab and ipilimumab with and without camu camu in first-line treatment of metastatic renal cell carcinoma (mRCC).
    Barragan-Carrillo, Regina
    Chawla, Neal Shiv
    Salgia, Nicholas
    Meza, Luis A.
    Zengin, Zeynep Busra
    Li, Xiaochen
    Dizman, Nazli
    Ebrahimi, Hedyeh
    Hsu, Joann
    Castro, Daniela V.
    Mercier, Benjamin D.
    Dorff, Tanya B.
    Tripathi, Abhishek
    Bergerot, Cristiane Decat
    Bergerot, Paulo Gustavo
    Chehrazi-Raffle, Alex
    Pal, Sumanta Kumar
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : TPS491 - TPS491
12345